← All organizations
Highest phase reached
Phase 3
First clinical trial
May 31, 2019Last known activity
Jul 8, 2021
Timeline
2000s
- Jun 1, 2002
NKMAX Co., Ltd.— Founded
Drugs by trial phase (7 distinct, 6 trials)
Phase 3 (1 own, 0 via acquisition)
Phase 2 (5 own, 0 via acquisition)
Phase 1 (1 own, 0 via acquisition)
Indications
Studied for
- Alzheimer Disease
- Breast Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Squamous Cell
- Cognitive Dysfunction
- Colorectal Neoplasms
- Endometrial Neoplasms
- Esophageal Neoplasms
- Infections
- Lung Neoplasms
- Neoplasm Metastasis
- Neoplasms
- Neurodegenerative Diseases
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Psoriasis
- Sarcoma
- Squamous Cell Carcinoma of Head and Neck
- Stomach Neoplasms
- Triple Negative Breast Neoplasms
- Urinary Bladder Neoplasms
- Uterine Cervical Neoplasms
Recent trials (7)
- NCT04872634Lead sponsorPhase 1/Phase 2Jul 8, 2021
- NCT04464967Study directorPhase 1/Phase 2Mar 31, 2021
- NCT04464967Lead sponsorPhase 1/Phase 2Mar 31, 2021
- NCT04678453Lead sponsorPhase 1Dec 31, 2020
- NCT04442048CollaboratorPhase 3Jun 25, 2020
- NCT03894579Lead sponsorPhase 1May 31, 2019
- NCT03941262Lead sponsorPhase 1May 31, 2019
Details
- Founded
- Seongnam-Si, KR Jun 1, 2002
- Last known activity
- Jul 8, 2021